Welton Pharma
October 17, 2023
Franciscan C
Oncology
Company Description: Welton Pharma is pre-clinical company developing our lead asset WP-038 for the treatment of colorectal cancer. Our patent-protected drug product is expected to increase the response rate in patients with colorectal cancer by ~300%. We have an experienced team with extensive manufacturing and regulatory experience, including a former FDA reviewer. We presently raising our $2.5M Seed round to advance our lead asset to IND-enabling studies.
Speakers
State
Florida
Country
United States
Website
http://www.weltonpharma.com
CEO/Top Company Official
Art Tipton
Lead Product in Development
WP-038
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
1
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)